SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after the announcement of disappointing trial results for Pemvidutide [4][6]. Group 1: Company Overview - Altimmune, Inc. is a publicly traded company listed on NASDAQ under the ticker symbol ALT [4]. - The company recently reported topline results from the IMPACT Phase 2b MASH trial, which did not meet statistical significance for its primary endpoint [6]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $75,000 in Altimmune between August 10, 2023, and June 25, 2025, to discuss their legal options [1][4]. - There is a deadline of October 6, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Altimmune [4]. Group 3: Stock Performance - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price plummeted from $7.71 per share to $3.61 per share, marking a decline of 53.2% in just one day [7].